The Hydrophobic Extract of Sorghum bicolor (L. Moench) Enriched in Apigenin-Protected Rats against Aflatoxin B1-Associated Hepatorenal Derangement

Aflatoxin B1 (AFB1) is a recalcitrant metabolite produced by fungi species, and due to its intoxications in animals and humans, it has been classified as a Group 1 carcinogen in humans. Preserving food products with Sorghum bicolor sheath can minimise the contamination of agricultural products and avert ill health occasioned by exposure to AFB1. The current study investigated the ameliorating effect of Sorghum bicolor sheath hydrophobic extract (SBE-HP) enriched in Apigenin (API) on the hepatorenal tissues of rats exposed to AFB1. The SBE-HP was characterised using TLC and LC-MS and was found to be enriched in Apigenin and its methylated analogues. The study used adult male rats divided into four experimental cohorts co-treated with AFB1 (50 µg/kg) and SBE-HP (5 and 10 mg/kg) for 28 days. Biochemical, enzyme-linked immunosorbent assays (ELISA) and histological staining were used to examine biomarkers of hepatorenal function, oxidative status, inflammation and apoptosis, and hepatorenal tissue histo-architectural alterations. Data were analysed using GraphPad Prism 8.3.0, an independent t-test, and a one-way analysis of variance. Co-treatment with SBE-HP ameliorated an upsurge in the biomarkers of hepatorenal functionality in the sera of rats, reduced the alterations in redox balance, resolved inflammation, inhibited apoptosis, and preserved the histological features of the liver and kidney of rats exposed to AFB1. SBE-HP-containing API is an excellent antioxidant regiment. It can amply prevent the induction of oxidative stress, inflammation, and apoptosis in the hepatorenal system of rats. Therefore, supplementing animal feeds and human foods with SBE-HP enriched in Apigenin may reduce the burden of AFB1 intoxication in developing countries with a shortage of effective antifungal agents.


Introduction
Aflatoxins (AFs) are mycotoxins produced by fungi species, especially the genus Aspergillus, including A. flavus, A. parasiticus, A. nomius, A. niger, and A. pseudotamarii [1][2][3]. The biosynthesis of AFs by fungi is driven under certain climatic conditions, including a temperature range of 25-35 • C and relative humidity of 80 to 100%, as typical in Sub-Saharan Africa [2,4], resulting in food spoilage [2,5,6] and significant economic loss [7]. AFs are classified, based on absorbance wavelengths and chromatographic mobility, into aflatoxin B 1 (AFB 1 ), aflatoxin B 2 (AFB 2 ), aflatoxin G 1 (AFG 1 ), and aflatoxin G 2 (AFG 2 ). In this classification guideline, the letters 'B' and 'G' are delineated as blue and green matic rings and phenolic groups [36]. These properties endow the leaf sheath extract of S. bicolor with high antioxidant potential and increase its free radical scavenging activity against ROS such as hydroxyl radicals and superoxide anions [37], one of the chief culprits of AFB 1 -induced hepatorenal toxicities. Experimental studies revealed that extracts of Sorghum bicolor (S. bicolor) significantly diminished ROS production by immune cells [37]. This report demonstrates the anti-inflammatory and immunomodulatory properties. Recently our laboratory developed a method to separate phytochemicals in S. bicolor into apigeninidin-enriched alcoholic extracts and a hydrophobic (CH 2 Cl 2 ) extract (S. bicolor extract-SBE-HP). We observed that apigeninidin-enriched extracts of the plant protected the liver and kidney of male rats from AFB 1 -mediated increase in hepatorenal dysfunctional molecules, generation of ROS, pro-inflammatory molecules, and apoptotic proteins [30]. To further probe the ethnomedicinal benefits of the SBE-HP, we herein characterised the components of this hydrophobic extract using chromatographic and LC-MS techniques. We found SBE-HP devoid of apigeninidin and enriched in apigenin and apigenin analogues. Subsequently, we investigated the potential impact of this apigenin-rich SBE-HP in abating liver and kidney derangements following sub-acute exposure to AFB 1 in male Wistar rats. The intention is to determine if SBE-HP could abrogate the AFB 1 -induced liver and kidney toxicities via antioxidative, anti-inflammatory, and apoptotic mechanisms. To this end, we treated rats with AFB 1 and SBE-HP for 28 days and evaluated the effect of this treatment on endogenous antioxidant defence systems and levels of anti-inflammatory cytokines. We observed that SBE-HP improved endogenous antioxidant defence systems and upregulated anti-inflammatory cytokines while reversing the basal concentrations of hepatorenal dysfunction molecules, ROS, pro-inflammatory and apoptotic mediators, and histological lesions in the liver and kidney of rats challenged with AFB 1 .
Molecules 2023, 28, x FOR PEER REVIEW 3 of 23 Figure 1. Metabolism of AFB1. Following chronic exposure to AFB1, AFB1 is rapidly absorbed into the enterocytes by passive diffusion and is absorbed into the liver for metabolism by arrays of CYP isoforms. Specifically, NADPH-dependent reductase converts AFB1 into aflatoxicol (AFL), CYP3A4 and CYP1A2 convert AFB1 into aflatoxin Q1 (AFQ1), CYP1A1 and CYP1A2 convert AFB1 into aflatoxin M1 (AFM1), or aflatoxin P1 (AFP1) through an O-demethylation reaction. These intermediates are clinically irrelevant as they are not heavily implicated in mutagenicity, carcinogenicity, and teratogenicity. The hepatic expression of CYP1A1, CYP1A2, CYP2E6, CPY3A4, and CYP3A5 is associated with AFBO formation, a clinically relevant intermediate, implicated in AFB1 toxicity and carcinogenicity. The mechanisms of AFBO toxicity are through the formation of protein adducts, DNA adducts, and lipid peroxidation. Specifically, epoxide hydrolase at PH 7.4 hydrolyses AFBO to AFB1 8,9-dihydrodiol, which can form a Schiff's base with primary amino groups in lysine residues, forming a protein adduct with lysine. This adduct is known to inhibit protein synthesis. In addition, AFBO binds to the guanine of DNA and forms a DNA adduct known Figure 1. Metabolism of AFB1. Following chronic exposure to AFB1, AFB1 is rapidly absorbed into the enterocytes by passive diffusion and is absorbed into the liver for metabolism by arrays of CYP isoforms. Specifically, NADPH-dependent reductase converts AFB1 into aflatoxicol (AFL), CYP3A4 and CYP1A2 convert AFB1 into aflatoxin Q1 (AFQ1), CYP1A1 and CYP1A2 convert AFB1 into aflatoxin M1 (AFM1), or aflatoxin P1 (AFP1) through an O-demethylation reaction. These intermediates are clinically irrelevant as they are not heavily implicated in mutagenicity, carcinogenicity, and teratogenicity. The hepatic expression of CYP1A1, CYP1A2, CYP2E6, CPY3A4, and CYP3A5 is associated with AFBO formation, a clinically relevant intermediate, implicated in AFB 1 toxicity and carcinogenicity. The mechanisms of AFBO toxicity are through the formation of protein adducts, DNA adducts, and lipid peroxidation. Specifically, epoxide hydrolase at PH 7.4 hydrolyses AFBO to AFB 1 8,9-dihydrodiol, which can form a Schiff's base with primary amino groups in lysine residues, forming a protein adduct with lysine. This adduct is known to inhibit protein synthesis. In addition, AFBO binds to the guanine of DNA and forms a DNA adduct known as 8,9-dihydro-8-(N 7 -guanyl)-9hydroxy-AFB1, leading to double-strand break, point mutation, activation of pro-oncogenes, and suppression of tumour suppressor genes. There is a safe pathway (blue arrow) for degrading AFBO, mediated by GST, an enzyme that mediates the conjugation of AFBO and GSH to form the AFB1-S-G complex. MRP binds to this complex and removes them from the hepatocytes for excretion in the bile and urine. Created by ChemDraw.

Characterisation of the Key Components in SBE-HP
The identities of the key components in SBE-HP, a CH 2 Cl 2 extract of S. bicolor, were probed using a combination of TLC and LC-MS analyses. TLC using CH 2 Cl 2 /MeOH 12:1 revealed that the components of SBE_HP clustered into three spots with retention factors (Rf ) of 0.27, 0.83, and approx. 1 (migrated with the solvent front). The Rf 0.27 is identical to API in this solvent system (Figure 2A), suggesting that the SBE-HP components with this Rf contain API and close analogues. Subsequent LC-MS analysis revealed that the main components of SBE-HP are API, apigenin O-methyl ethers-acacetin and glycitein (or genkwanin), apigenin dimethyl ethers, hispidulin or luteolin methyl ethers, luteolin dimethyl ether, naringenin, 7-O-methyl apigeninidin, and protocatechuic acid methyl ester ( Figure 2B).

SBE-HP Prevented AFB1-Orchestrated Alterations in Body Weight and Organosomatic Indices, Rat Survivability, and Biomarkers of Hepatorenal Functions in Rats
The preventive effects of SBE-HP on AFB 1 -induced hepatorenal derangements in adult male Wistar rats were investigated in the current study. We explored the abrogative potential of SBE-HP on body weight and organosomatic indices ( Figure 3B), overall survival ( Figure 3C), and biomarkers of the functions and integrity of the hepatorenal system ( Figure 4) in rats. Our results showed that the mean final body weights of the experimental animals increased significantly (p < 0.05) in all groups compared to the initial body weight of rats. However, there was no significant difference (p > 0.05) in the mean organ weight and relative organ weight of rats. Compared to the control, AFB 1 slightly decreased the mean weight change of rats. However, this was abated in the group treated with only 5 mg/kg SBE-HP ( Figure 3B). Despite the slight decrease in organ-to-somatic ratio and mean body weights, rats had no mortality during the study period, indicating 100% overall survival ( Figure 3C). In addition, the administration of AFB 1 significantly increased (p < 0.0001) the serum activities and levels of ALT, AST, ALP, urea, and creatinine compared to the control, indicative of hepatorenal toxicities. However, this was counterbalanced by SBE-HP at 5 and 10 mg/kg. At 5 mg/kg, SBE-HP significantly decreased the serum activities and levels of ALT (p < 0.001), AST (p = 0.0387), ALP (p < 0.0001), urea (p = 0.0124), and creatinine (p < 0.0001) compared to the cohort of rats treated with alone AFB 1 . The restoration in the serum concentrations of these hepatic and renal function biomarkers was significantly prominent (p < 0.0001) in a cohort of rats co-treated with 10 mg/kg SBE-HP compared to the AFB 1 alone group (Figure 4). dimethyl ether, naringenin, 7-O-methyl apigeninidin, and protocatechuic acid methyl ester ( Figure 2B). increased (p < 0.0001) the serum activities and levels of ALT, AST, ALP, urea, and creatinine compared to the control, indicative of hepatorenal toxicities. However, this was counterbalanced by SBE-HP at 5 and 10 mg/kg. At 5 mg/kg, SBE-HP significantly decreased the serum activities and levels of ALT (p < 0.001), AST (p = 0.0387), ALP (p < 0.0001), urea (p = 0.0124), and creatinine (p < 0.0001) compared to the cohort of rats treated with alone AFB1. The restoration in the serum concentrations of these hepatic and renal function biomarkers was significantly prominent (p < 0.0001) in a cohort of rats co-treated with 10 mg/kg SBE-HP compared to the AFB1 alone group (Figure 4).

SBE-HP Mitigates Oxidative Stress and Restores Antioxidant Activities and Levels in the Liver and Kidney of AFB1-Treated Rats
The induction of oxidative stress is a probable mechanism of action of AFB1-induced hepatic and renal derangements. To this end, we probed the mitigating effect of SBE-HP against AFB1-mediated oxidative stress in rats' hepatic and renal tissues, as presented in Figures 5-7. In comparison to the control, our results showed that AFB1 significantly decreased (p < 0.0001) the hepatic activities of SOD, CAT, and GPx as well as the renal activities of SOD (p = 0.0084), CAT (p < 0.0001), and GPx (p < 0.0001) in rats, denoting the induction of oxidative stress. However, the administration of SBE-HP at 5 and 10 m/kg restores the activities of these antioxidants. At 5 mg/kg, SBE-HP increased the activities of Experimental doses: AFB 1 at 50 µg/kg; SBE-HP-D1 at 5 mg/kg; SBE-HP-D2 at 10 mg/kg. Values are expressed as mean ± SD for six rats per treatment cohort. Connecting lines indicate groups compared to one another. The significance level was set at (p < 0.05); p < 0.05 suggests the level of significance; p > 0.05: not significant. AFB 1 : Aflatoxin B1; D1: lower dose; D2: higher quantity; ALT: Alanine aminotransferase; AST: aspartate aminotransferase, ALP: Alkaline phosphatase; GGT: gamma-glutamyl transferase.

SBE-HP Mitigates Oxidative Stress and Restores Antioxidant Activities and Levels in the Liver and Kidney of AFB 1 -Treated Rats
The induction of oxidative stress is a probable mechanism of action of AFB 1 -induced hepatic and renal derangements. To this end, we probed the mitigating effect of SBE-HP against AFB 1 -mediated oxidative stress in rats' hepatic and renal tissues, as presented in Figures 5-7. In comparison to the control, our results showed that AFB 1 significantly Molecules 2023, 28, 3013 7 of 21 decreased (p < 0.0001) the hepatic activities of SOD, CAT, and GPx as well as the renal activities of SOD (p = 0.0084), CAT (p < 0.0001), and GPx (p < 0.0001) in rats, denoting the induction of oxidative stress. However, the administration of SBE-HP at 5 and 10 m/kg restores the activities of these antioxidants. At 5 mg/kg, SBE-HP increased the activities of SOD (p < 0.0001), CAT (p > 0.6186), and GPx (p > 0.9999) compared to the AFB 1 alone group. However, at a higher concentration of SBE-HP (10 mg/kg), the activities of SOD, CAT, and GPx were prominent (p < 0.0001) relative to AFB 1 alone treated rats ( Figure 5). Furthermore, our results divulged that AFB 1 markedly waned (p < 0.0001) the activities of GST (a phase-2 antioxidant molecule) and the levels of GSH and TSH in the liver and kidney of rats compared to the untreated group. In contrast, the co-ingestion of SBE-HP at the tested doses resulted in a positive trend in GST activity and GSH and TSH levels in the liver and kidney of rats. Rats co-treated with 5 mg/kg SBE-HP showed increased hepatic GST activity (p = 0.0501) and GSH (p < 0.0001) and TSH (p < 0.0001) levels. Renal GST activity (p = 0.0008) and GSH (p > 0.9999) and TSH (p = 0.0007) levels were also increased compared to the AFB 1 alone treated group. The observed effects on GST activity and GSH and TSH levels were further reinforced (p < 0.001) in cohorts of rats co-treated with 10 mg/kg in the liver and kidney tissues of rats relative to the AFB 1 alone treated rats ( Figure 6). In addition, for oxidative stress to manifest in rats exposed to toxicants, there must be an imbalance between antioxidants and pro-oxidants in favour of pro-oxidants. In the current study, AFB 1 significantly elevated (p < 0.0001) the hepatic and renal levels of LPO and RONS compared to the control. Nevertheless, co-treatment with SBE-HP offset this effect, thus scavenging available free radicals in the liver and kidney of rats. Specifically, co-treatment at 5 mg/kg waned the hepatic levels of LPO (p = 0.0070) and RONS (p < 0.0001) as well as significantly decreased (p < 0.0001) the renal levels of LPO and RONS relative to the AFB 1 treated group. Furthermore, at 10 mg/kg, the decline in the levels of LPO and RONS was significantly prominent (p < 0.0001) compared to the AFB 1 alone group in the liver and the kidney tissues, indicating that the extract mediates the antioxidative effect ( Figure 7).
Molecules 2023, 28, x FOR PEER REVIEW 8 of 23 RONS (p < 0.0001) as well as significantly decreased (p < 0.0001) the renal levels of LPO and RONS relative to the AFB1 treated group. Furthermore, at 10 mg/kg, the decline in the levels of LPO and RONS was significantly prominent (p < 0.0001) compared to the AFB1 alone group in the liver and the kidney tissues, indicating that the extract mediates the antioxidative effect ( Figure 7).   Effect of SBE-HP on the tissue concentrations of CAT, SOD, and GPx in the liver and kidney of rats treated with AFB1 for 28 d. AFB1 at 50µg/kg; SBE-HP-D1 at 5 mg/kg; SBE-HP-D2 at 10 mg/kg. Values are expressed as mean ± SD for six rats per treatment cohort. Connecting lines indicate groups compared to one another. The significance level was set at (p < 0.05); p < 0.05 indicates the level of significance; p > 0.05: not significant. AFB1: Aflatoxin B1; D1: lower dose; D2: higher dose; SOD: Superoxide dismutase; CAT: Catalase; GPx: Glutathione peroxidase.

SBE-HP Resolves Inflammation and Abrogates Apoptosis in the Liver and Kidney of AFB1-Treated Rats
In the current study, we hypothesise that unquenched free radicals may trigger the release of pro-inflammatory molecules and initiate the programmed cell death pathways through extrinsic or intrinsic pathways. We, therefore, probe the ameliorative effect of SBE-HP against AFB1-mediated inflammation and apoptosis, as shown in Figures 8-10. The treatment of rats with AFB1 significantly increased pro-inflammatory mediators,

SBE-HP Resolves Inflammation and Abrogates Apoptosis in the Liver and Kidney of AFB 1 -Treated Rats
In the current study, we hypothesise that unquenched free radicals may trigger the release of pro-inflammatory molecules and initiate the programmed cell death pathways through extrinsic or intrinsic pathways. We, therefore, probe the ameliorative effect of SBE-HP against AFB 1 -mediated inflammation and apoptosis, as shown in Figures 8-10. The treatment of rats with AFB 1 significantly increased pro-inflammatory mediators, including XO, MPO, and NO, compared to the untreated group (p < 0.0001). However, co-treatment with SBE-HP counteracted the upsurge in pro-inflammatory mediators at the test doses. Specifically, 5 and 10 mg/kg of SBE-HP markedly waned (p < 0.0001) the activities of XO and MPO and the level of NO in the liver and kidney compared to the cohort of rats treated with AFB 1 , with the higher dose (10 mg/kg) exhibiting higher anti-inflammatory property ( Figure 8). We hypothesise that the pro-inflammatory and anti-inflammatory cytokines ratio may induce hepatorenal toxicity. To this end, we probe the effect of SBE-HP in lowering the proportion of pro-inflammatory cytokines to anti-inflammatory in rats exposed to AFB 1 . Compared to the control, the rat cohort treated with AFB 1 alone exhibited increased levels of IL-1β in the liver (p = 0.0031) and in the kidney (p < 0.0001) while reducing the level of IL-10 in the liver (p = 0.0014) and the kidney (p = 0.0003). In contrast, cohorts of rats co-treated with SBE-HP at the test doses decreased the hepatic and renal levels of IL-1β while elevating IL-10. At 5 mg/kg, SBE-HP reduced the level of IL-1β in the liver (p = 0.2208) and kidney (p = 0.0018) while increasing the level of IL-10 in the liver (p = 0.024) and kidney (p = 0.0043) of rats compared to AFB 1 alone treated rats. The anti-inflammatory effect of SBE-HP was more prominent in cohorts of animals co-treated at 10 mg/kg, as this dose decreased the level of IL-1β in the liver (p = 0049) and kidney (p < 0.0001) while increasing the level of IL-10 in the liver (p < 0.0001) and kidney (0.0004). SBE-HP at both doses lowered IL-1β/IL-10, favouring anti-inflammatory cytokines ( Figure 9). In addition, we hypothesised that if oxidative stress and inflammation are not resolved, they may drive apoptosis and therefore probe that SBE-HP can inhibit the ability of AFB 1 to orchestrate apoptosis in the liver and kidney of rats. Our results showed that AFB 1 , compared to the untreated group, triggered apoptosis by increasing the hepatic activities of caspase-9 and caspase-3 (p < 0.0001) as well as renal activities of caspase-9 (p = 0.0018) and caspase-3 (p < 0.0001) compared to the control. In contrast, SBE-HP at the tested doses prevented apoptosis in the liver and kidney of rats. Cohorts of rats co-treated with 5 mg/kg SBE-HP decreased hepatic activities of caspase-9 (p = 0.0062) and caspase-3 (p = 0.0008) and renal activities of caspase-9 (p = 0.0283) and caspase-3 (p = 0.0020) compared to the AFB 1 alone treated rats. This effect was enhanced in cohorts of rats co-treated with 10 mg/kg SBE-HP as this decreased the hepatic activities of caspase-9 and caspase-3 (p < 0.0001) as well as hepatic activities of caspase-9 (p = 0.0012) and caspase-3 (p < 0.0001) relative to the AFB 1 alone treated rats ( Figure 10).

SBE-HP Abrogates Histological Lesions in the Liver and Kidney of AFB 1 -Exposed Rats
Finally, we probe that exposure to AFB 1 after 28 days can orchestrate alterations in the architectural structures of the kidney and liver tissues and that co-treatment with SBE-HP can reduce the burden of AFB 1 -hepatorenal toxicity and preserve the architectural forms of the rat kidney and liver, as presented in Figure 11a,b. In comparison to the untreated group, cohorts of rats treated with AFB 1 manifested dispersed glomerular messangialisation and infiltration of intraglomerular mesangial cells into the cortex in the kidney tissues (Figure 11a), as well as focal congestion, trafficking, and infiltration of Kupffer cells into zone 2, slight ballooning and degeneration of the liver cells and micro-vesicular steatosis in the liver tissues ( Figure 11b). However, SBE-HP at 5 and 10 mg/kg minimised AFB1mediated toxicities and preserved the histoarchitectural structures of the liver and kidney tissues, approximating histo-architecture like the control.
activities of caspase-9 (p = 0.0018) and caspase-3 (p < 0.0001) compared to the control. I contrast, SBE-HP at the tested doses prevented apoptosis in the liver and kidney of rat Cohorts of rats co-treated with 5 mg/kg SBE-HP decreased hepatic activities of caspase-(p = 0.0062) and caspase-3 (p = 0.0008) and renal activities of caspase-9 (p = 0.0283) an caspase-3 (p = 0.0020) compared to the AFB1 alone treated rats. This effect was enhance in cohorts of rats co-treated with 10 mg/kg SBE-HP as this decreased the hepatic activitie of caspase-9 and caspase-3 (p < 0.0001) as well as hepatic activities of caspase-9 (p = 0.0012 and caspase-3 (p < 0.0001) relative to the AFB1 alone treated rats ( Figure 10).    . Effect of SBE-HP on tissue concentrations of IL-1β and IL-10 in the liver and kidney of rats treated with AFB1 for 28 d. AFB1 at 50 µg/kg; SBE-HP-D1 at 5 mg/kg; SBE-HP-D2 at 10 mg/kg. Values are expressed as mean ± SD for six rats per treatment cohort. Connecting lines indicate groups compared to one another. The significance level was set at (p < 0.05); p < 0.05 suggests the level of significance; p > 0.05: not significant. AFB1: Aflatoxin B1; D1: lower dose; D2: higher dose; IL-1β: Interleukin-1beta; IL-10: Interleukin-10.

SBE-HP Abrogates Histological Lesions in the Liver and Kidney of AFB1-Exposed Rats
Finally, we probe that exposure to AFB1 after 28 days can orchestrate alterations in the architectural structures of the kidney and liver tissues and that co-treatment with SBE-HP can reduce the burden of AFB1-hepatorenal toxicity and preserve the architectural forms of the rat kidney and liver, as presented in Figure 11a,b. In comparison to the untreated group, cohorts of rats treated with AFB1 manifested dispersed glomerular messangialisation and infiltration of intraglomerular mesangial cells into the cortex in the kidney tissues (Figure 11a), as well as focal congestion, trafficking, and infiltration of Kupffer cells into zone 2, slight ballooning and degeneration of the liver cells and microvesicular steatosis in the liver tissues ( Figure 11b). However, SBE-HP at 5 and 10 mg/kg minimised AFB1-mediated toxicities and preserved the histoarchitectural structures of the liver and kidney tissues, approximating histo-architecture like the control.

Discussion
Exposure of animals and humans to AFB1 continues to be of severe concern in semiarid tropical regions of Asia and Africa. Accidental ingestion of AFB1 through contaminated food products can cause toxicity to organs such as the liver, kidney, hypothalamus, testis, epididymis, and heart [21,22,24,27]. The concomitant effects of AFB1-induced toxicities include growth retardation, malnutrition, and immune suppression [15,16]. Efforts to reduce AFB1 contamination in food products have continually waned due to the recalcitrant nature of the fungal species that mediate the biosynthesis of mycotoxins [38,39] and the induction of metabolic pathways for the breakdown of AFB1 [30,33,40]. Bioactive compounds in plants can remediate AFB1-

Discussion
Exposure of animals and humans to AFB 1 continues to be of severe concern in semiarid tropical regions of Asia and Africa. Accidental ingestion of AFB 1 through contaminated food products can cause toxicity to organs such as the liver, kidney, hypothalamus, testis, epididymis, and heart [21,22,24,27]. The concomitant effects of AFB 1 -induced toxicities include growth retardation, malnutrition, and immune suppression [15,16]. Efforts to reduce AFB 1 contamination in food products have continually waned due to the recalcitrant nature of the fungal species that mediate the biosynthesis of mycotoxins [38,39] and the induction of metabolic pathways for the breakdown of AFB 1 [30,33,40]. Bioactive compounds in plants can remediate AFB 1 -mediated toxicities by inhibiting ROS production, resolution of inflammation, and preventing programmed cell death [41,42]. To further narrow the gap in the search for potential drug regimens that can effectively lessen the side events associated with AFB 1 toxicity, the current study explores the ameliorative effects of the SBE-HP against AFB 1 -mediated hepatorenal derangements. The results show slight alterations in mean body weight and organosomatic indices and a significant increase (p < 0.05) in the activities of liver and kidney function biomarkers (ALT, AST, ALP, urea, and creatinine). There was a considerable decrease (p < 0.05) in the levels of antioxidant (SOD, CAT, GPx, GST, GSH, and TSH) and anti-inflammatory (IL-10) biomarkers; a significant increase (p < 0.05) in the levels of oxidative stress (MDA, RONS), pro-inflammatory (XO, MPO, NO, and IL-1β), and apoptotic (caspase-9 and -3) biomarkers; atypical histological structures observed in AFB 1 alone treated group were reversed, counteracted, resolved, and refurbished by co-treatment with 5 and 10 mg/kg SBE-HP. This study established three definitive mechanisms for AFB 1 toxicities: high ROS generation, dampening the innate antioxidant defences, and activating pro-inflammatory molecules to activate, expand, and differentiate pro-inflammatory cells. Collectively, these caused the release of pro-inflammatory cells and increased the ratio of pro-inflammation to anti-inflammation in the hepatorenal system, resulting in the induction of apoptosis via the intrinsic or extrinsic pathway.
Oxidative stress is established when an imbalance between the antioxidant defence system and the pro-oxidants occurs [43,44]. AFB 1 is a known hepatoxic and nephrotoxic agent in humans and experimental animals [22,40,45]. AFB 1 toxicity stems from the activities of CYP540 isoforms, which mediate the bioactivation of AFB 1 into a toxic metabolite, AFBO [17,18]. Continual bioactivation of AFB 1 into AFBO by these enzymes releases superoxide anion radicals (O2 .-) into the hepatorenal system, thereby orchestrating SOD, an enzyme known to detoxify (O2 .-) into hydrogen peroxide (H 2 O 2 ), a less toxic free radical. The accumulation of H 2 O 2 rouses the catalase activity to degrade the hepatic and renal levels of H 2 O 2 into molecular water. GPx can detoxify H 2 O 2 in the presence of GSH or TSH. These innate antioxidant defence systems, including SOD, CAT, GPx, GSH, and TSH, were diminished, as seen in the current study. Concomitantly, free radicals accumulate in the hepatocytes and nephrons and trigger the formation of hydroxyl radicals (HO -) in the presence of ferrous ions (Fe 2+ ) in either the Haber-Weiss or Fenton reactions. These radicals interact with important biological molecules such as membrane lipids, proteins, and nucleic acids, triggering lipid peroxidation, as observed in this study. We observed that AFB1 significantly increased the hepatic and renal levels of MDA, a marker of lipid peroxidation and protein cross-link and DNA and RNA damage established in other studies [22,40]. These biochemical reactions evolve more ROS and RNS in the liver and kidney cells, further hampering the capacity of the innate antioxidant defence systems to mop up hepatic and renal free radicals.
As observed in this study following treatment with AFB1, a significant increase in RONS levels in tissues is correlated to hepatorenal toxicities [46]. Nevertheless, the toxicities associated with AFB 1 and AFBO can be averted by the phase-2 antioxidant defence system via the expression of GST. GST interaction with AFBO mediated by GSH and other sundry enzymes forms the AFB1-S-G complex. This complex binds to MRP or p-glycoprotein and is excreted in the bile and urine. This study shows that suppressing GST's hepatic and renal activities further exposes the target organs to ROS-mediated toxicities, as more AFBOs are formed with the simultaneous evolution of abundant free radicals. Findings from previous studies on the oxidative/nitrosative stress-promoting effects of AFB 1 in rats agree with our current observations [22,47,48].
Interestingly, we observed that cohorts of rats co-treated with SBE-HP at 5 and 10 mg/kg remediated oxidative/nitrosative stress in the liver and kidney tissues by significantly increasing the hepatic and renal levels of SOD, CAT, GPx, GSH, TSH, and GST. At the same time, SBE-HP markedly decreased LPO and RONS levels in rats' livers and kidneys. The observed antioxidative effect is attributed to the unique antioxidant activities of the key compounds in SBE-HP. API, apigenin methyl ether analogues (acacetin, glycitein (or genkwanin), apigenin dimethyl ethers, hispidulin or luteolin methyl ethers, luteolin dimethyl ether, naringenin, 7-O-methyl apigeninidin, and protocatechuic acid methyl ester identified in SBE-HP are antioxidants that have been previously detected in S. bicolor [49]. We show that API inhibited the activity of CYP1A2, one of the CYP isoforms involved in the bioactivation of AFB 1 into a toxic intermediate.
Unquenched oxidative/nitrosative stress could activate signalling pathways, especially NF-κB, a known regulator of inflammation [49], and other pro-inflammatory mediators, including MPO, XO, and NO [22]. MPO, a member of the heme peroxidase superfamily, is expressed in pro-inflammatory cells such as neutrophils and monocytes [50]. It mediates the biochemical reaction in which H 2 O 2 , in the presence of chlorine, is converted to hypochlorous acid (HOCl), which decomposes to release harmful free radicals, including 1 O 2 and OH. An increase in MPO activity during inflammation has been shown to drive oxidative stress by promoting the release of more harmful pro-oxidants in the target tissues [51]. The interaction of these pro-oxidants and other free radicals with nucleic acid precursors such as purine bases may increase the activity of XO in the target tissues, leading to the transformation of hypoxanthine and xanthine into their end-product, urea acid, with concomitant release of O 2 − . While O 2 − increases the hepatorenal system's oxidative and nitrosative stress burdens, uric acid acts as a danger-associated molecular pattern (DAMP) to activate several inflammasome pathways and NF-κB within the hepatorenal system and orchestrate the expression of pro-inflammatory mediators [52,53]. As a biomarker of hepatorenal derangements, an increase in the level of NO in the tissues of rats correlates with prolonged oxidative stress and inflammation [44,54]. Under the basal condition, NO mediates an anti-inflammatory effect and regulates several biochemical processes, including vasodilation in the cardiovascular system, neurotransmission in the central nervous system, and cytokine-mediated activation of macrophages in the immune system [55]. However, NO may accumulate and induce chronic inflammation in tissues exposed to oxidative and inflammatory stimuli. In addition, loss of redox homeostasis can trigger an increase in NO synthase activities, an enzyme that converts L-arginine to L-ornithine and NO in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and molecular O 2 as co-factors. As NO accumulates in the hepatorenal system, it interacts with O 2 .-and produces another toxic free radical, peroxynitrite (ONOO − ). These reactive nitrogen species (RNS) mediate chronic information through DNA damage, increased Cox-2 expression, elevation in the expression of pro-inflammatory cytokines, angiogenesis, and nitration of functional proteins in the hepatorenal tissues [21,56]. In our findings, AFB 1 orchestrated inflammation by increasing the hepatic and renal activities of MPO and XO and the levels of NO and IL-1β while decreasing the hepatic and renal levels of IL-10, an anti-inflammatory cytokine. These changes alter the pro-inflammatory/anti-inflammatory ratio favouring pro-inflammatory cues, thus increasing hepatic and renal inflammation. The induction of oxidative stress and subsequent inflammation creates suitable links between oxidative stress and inflammation. Alteration in the pro-inflammatory/anti-inflammatory ratio following exposure to AFB 1 was reverted and normalised in cohorts of rats treated with API-containing SBE-HP as hepatic and renal MPO, XO, NO, and IL-1β in these rats significantly waned while that of IL-10 increased markedly. These alterations may have been possible due to bioactive compounds' anti-inflammatory and antioxidative effects in the SBE-HP [30,36,57].
If the pro-oxidants resulting from the exposure to AFB 1 are not scavenged, the resultant pro-inflammatory cues in rats' liver and kidney tissues will not resolve. Signalling networks impairing mitochondrial dysfunction and committing cells to apoptosis may be switched upstream and downstream [58][59][60]. Specifically, free radicals produced during the metabolism of AFB 1 and activating pro-inflammatory cells may bind to DNA and functional proteins to trigger the formation of DNA adducts in rats' hepatic and renal tissues [22], causing genomic instability and committing the hepatocytes and nephrons to short-term cell cycle arrest. The duration of the cell cycle arrest will depend on when the AFB 1 insults are completely detoxified and removed. However, programmed cell death may ensue if these insults persist in the liver and kidney cells. Specifically, p53 directs the expression of PUMA (p53 upregulated modulator of apoptosis), which alters the Bax/Bcl-2 ratio in favour of Bax [61]. The translocation of Bax into the hepatic and renal cells mitochondria causes cytochrome C release into the cytoplasm, where it interacts with apoptotic peptidase activating factor 1 (APAF-1) pro-caspase-9, forming apoptosome and active caspase-9, the initiator of apoptosis. Caspase-9 then activates caspase-3, the executioner of apoptosis, thereby committing the cells to die. Based on this syllogism, previous studies infer that increased activities of Caspase-9 and -3 in hepatic and renal tissue are an indication of programmed cell death of the affected tissues [22,23,62,63], and this was validated in the current studies where we observed that ingestion of AFB1 to rats significantly increased the activities of caspase-9 and -3. Any compound that can dampen the actions of these caspases could possess anti-apoptotic activity and might be used to construct a novel biologic against AFB intoxication.
Interestingly, the current study's findings reveal that co-treatment of rats exposed to AFB 1 with API-containing SBE-HP significantly decreased the activities of caspase-9 and -3, indicating an interruption in AFB1-mediated apoptosis and restoration of wholeness to the hepatorenal system. The role of bioactive compounds in S. bicolor on apoptosis depends on cell types. In normal hepatic and renal tissues, S. bicolor mediates the anti-apoptotic effect, thereby preserving the tissues from environmental toxicants capable of committing a cell to apoptosis. However, in tumours, these plant extractives portend a pro-apoptotic function, thus enhancing the death of cancer cells [30,39,64].
Alterations in the typical histological features of the liver and kidney tissues are clinically relevant in assessing the toxicities of AFB 1 . It also validates the outcomes of numerous biochemical assays, as established in this study. During oxidative stress, inflammation, and apoptosis, DAMPs are released into the cells, interacting with pattern recognition receptors expressed on the surface of pro-inflammatory cells [65,66]. The Kupffer cells and intraglomerular mesangial cells activate, proliferate, and differentiate into pro-inflammatory phenotypes in the liver and kidney. These cells release abundant soluble factors, including IL-1β, TNF-α, IL-17, IL-6, IL-8, NO, Cox-2, and PGE 2, into the hepatocytes and nephrons, thus making the cell lose their normal histology [30], as seen in the current study. However, this effect was minimised by SBE-HP through the resolution of inflammation, inhibition of oxidative stress, and apoptosis, further validating the plant's antioxidative, anti-inflammatory, and anti-apoptotic effects.

Collection, Identification, and Processing of Plant Sample
Overall, 5 kg dried S. bicolor sheaths were purchased from Bodija Market, Ibadan, Oyo State, Nigeria. The samples were brought to the Department of Botany, the University of Ibadan, Ibadan, Nigeria, in a polythene bag for taxonomist identification, and a voucher specimen (Accession No: UIH-23118) was deposited there for reference purposes. The plant was sorted to remove dirt and other extraneous materials and ground into fine powder.

Extraction and Phytochemical Characterisation of S. bicolor
SBE-HP was obtained as a CH 2 Cl 2 extract of S. bicolor, as described previously [30]. The isolated brownish-red paste was analysed by thin-layer chromatography (TLC) (Supelco, TLC Silica gel 60 F 254 , 1.05554.0001; Sigma-Aldrich) and LC-MS (Figure 2A,B). For LC-MS analysis, 0.6 mL isopropanol, one scoop of 0.5 mm glass beads, and one scoop of 2 mm ZrO beads were added to the SBE-HP sample in a microcentrifuge vial. The mixture was homogenised in a Tissuelyzer II at 30 Hz for 5 min, vortexed, centrifuged at 21,100× g for 5 min, and transferred to an LC vial for analysis. Chromatography was performed on a Waters BEH C18 100 × 2.1 mm, a 1.7-micron column with Mobile Phase A: 60%acetonitrile 40%water 0.1% FA 10 mM ammonium formate and Mobile Phase B: 10% ACN 90% IPA, 0.1% FA 10 mM ammonium formate. The column temperature was maintained at 60 • C, and a 0.5 µL sample was injected for each run. MS data were acquired in positive and negative ion modes.

Animal Welfare, Sample Size Estimation, and Experimental Design
The 3R's protocols, including replacement, reduction, and refinement, were adopted in this study. The sample size was estimated using the G*Power software version 3.1.9.4 [67]. With an effect size of 0.40, 95% power, and 0.05 p-value for one-way analysis of variance (ANOVA) [42], a sample size of 125 was estimated. Of this calculated value, 24 adult male Wistar Albino rats (consisting of n = six rats, i = 4) with a mean weight of approximately 165 g b.w. were bought from the experimental animal facility of the Faculty of Veterinary Medicine, University of Ibadan, Nigeria. The experimental rats were kept in the animal facility of the Department of Biochemistry, Faculty of Basic Medical Sciences, University of Ibadan, Nigeria, and humanely maintained in natural photoperiod conditions. Rats were fed with standard chows, allowed access to clean water ad libitum, and then acclimatised for 14 days before dosing with AFB 1 and the hydrophobic S. bicolor extract (SBE-HP). The study was conducted in line with the ethics of animal use as certified by the Animal Care and Use Research Ethics Committee (ACUREC) of the University of Ibadan (Approval number: UI-ACUREC/032-0521/7).

Termination of the Experiment, Organ Harvest, and Tissue Processing
At the expiration of 28 d, all the rats' final body weight was measured 24 h after the last intubation, followed by exsanguination through the retro-orbital venous plexus system into well-labelled non-heparinised tubes. Afterwards, the rats were sacrificed through cervical dislocation. The whole blood was allowed to clot at 25 • C for 30 min, and the coagulated blood was subjected to centrifugation at 3000× g for 10 min at 4 • C. The clear supernatant (serum) was transferred into clean labelled Eppendorf tubes and preserved at −20 • C before quantifying the biomarkers of hepatorenal functions. In addition, the liver and kidney of the sacrificed rats were instantly removed, cleaned in ice-cold KCl solution, and then weighed using a USS-DBS16 Analytical Balance (Cleveland, OH, USA). The relative organ weights of the liver and kidney were determined as follows: Organ weight Relative to the bodyweight = Weight of organ (g) Weight of the body (g) × 100.
Portions of the liver and kidney were used for biochemical and histological investigations. Samples for biochemical estimations were prepared by homogenising in a phosphate buffer (0.1 M, pH 7.4). The tissue homogenate was prepared by homogenising the liver (2 g in 8 mL of phosphate buffer) and the kidney (1.12 g in 4 mL of phosphate buffer) using a glass-Teflon homogeniser. The resultant homogenates were centrifuged at 12,000 rpm at 4 • C for 15 min to obtain a clear mitochondrial fraction. The supernatants were collected in aliquots and frozen before quantifying oxidative, inflammatory, and apoptotic biomarkers.

Estimation of Function and Integrity of the Hepatorenal System
The functionality and integrity of the liver and kidney of rats co-exposed to AFB 1 and SBE-HP after 28 d was evaluated by measuring the activities and levels of ALT, AST, ALP, creatinine, and urea using commercial kits as previously reported [22].

Estimation of the Biomarkers of Oxidative Stress, Inflammation, and Apoptosis
The oxidative stress, inflammation, and apoptosis levels were measured in the liver and kidney of rats co-exposed to AFB 1 and SBE-HP post 28 d. The levels of total protein in the liver and kidney of rats were estimated according to the method described by ref. [46]; hepatic and renal activities of superoxide dismutase (SOD) were assessed by the methods described by Misra and Fridovich [70], as previously reported [71]; hepatic and renal activities of catalase (CAT) were assessed by the protocols of Clairborne [72] using H 2 O 2 as a substrate as previously reported [73]; hepatic and renal activities of Glutathione-Stransferase (GST) and glutathione peroxidase (GPx) were quantified by the procedures of Habig [74] and Rotruck et al. [75], respectively, as previously reported [76]; hepatic and renal levels of reduced glutathione (GSH) and total sulfhydryl group (TSH) were estimated by the method of Jollow et al. [77] and Ellman [78], as previously reported [22,57]; hepatic and renal activities of xanthine oxidase (XO) were measured by the procedures of Bergmeyer et al. [79]; hepatic and renal levels of malondialdehyde (MDA), otherwise termed lipid peroxidation (LPO) were assessed by the method described by Okhawa [80]; hepatic and renal levels of reactive oxygen and nitrogen species (RONS) were assayed by the protocols of Owumi and Dim [81]; hepatic and renal nitric oxide (NO) level and myeloperoxidase (MPO) activity were quantified by the protocols of Green et al. [60,82] and Granell et al. [83,84], respectively, as previously reported by Owumi et al. [85]; hepatic and renal levels of IL-1β and IL-10 and the caspase-9 and -3 activities were assayed using ELISA kits, as previously reported [22]. All measurements were carried out using a Spectra Max TM plate reader.

Examination of the Histological Sections of the Liver and Kidney
The portions of the liver and kidney for histological assessment were fixed in neutral buffered formalin (10%) before the preparation of histological sectioning and staining. With the aid of a standard paraffin-wax method, the hepatic and renal tissues were processed for histopathological examination in line with the description of Bancroft and Gamble [86]. Approximately five µm thickness of the portion of the liver and kidney were dyed with haematoxylin and eosin and processed for light microscopy. All prepared slides were coded and probed with a Carl Zeiss Axio light microscope (Gottingen, Germany). On inspection, images were taken using a Zeiss Axiocam 512 camera (Gottingen, Germany) attached to the microscope by a pathologist unaware of the various treatment cohorts from which the slides were prepared.

Statistical Analysis of Results
At the end of the experiments, data were generated, quantified, and subjected to statistical analyses using quantitative measures such as mean and standard deviation. The results were expressed as the mean ± SD of replicates. A test of statistical inferences was performed by student t-test to compare the significance between the initial body weight (IBW) and final body weight (FBW) of rats. A one-way analysis of variance (ANOVA) followed by a post hoc test (Tukey's test) set at a 95% probability level was used to test the significance difference across the four experimental groups using GraphPad Prism, version 8.3.0 for Mac (www.graphpad.com, accessed on 9 July 2022; GraphPad, San Diego, CA, USA).

Conclusions
We have shown that API-containing SBE-HP prevented, in adult male Wistar Albino rats, oxidative/nitrosative stress, inflammation, and apoptosis induction. The probable mechanisms may be activating the aryl hydrocarbon receptor (which promotes IL-10 expression), de-repression of estrogen receptor alpha (known to mediate anti-inflammatory activity), activation of the expression of p53 and mitochondrial membrane potential, and upregulation of Nrf2, NQO1, and HO-1 signalling. At the same time, mediating the suppression of cytochrome P450 (CYP) 1A2 expression, inhibition of NF-kB, upregulation of Bax expression and the activities of caspase-3 and caspase-3 and suppression of signalling along JNK, p38 MAKP, ERK, and Keap1 axis as depicted in our proposed mechanism of protection Figure 12. These findings recapitulate the ethnomedicinal relevance of the SBE-HP and emphasise its usefulness in preventing AFB 1 intoxications, including hepatic steatosis, hepatitis, cirrhosis, hepatocellular carcinoma, and glomerulonephritis in animal and human models. Finally, our studies validate the three defined mechanisms of AFB 1 intoxications, including oxidative stress, inflammation, and apoptosis, and warrant further investigation to explore more mechanistic pathways of AFB1 intoxication in rats and other experimental models.  Informed Consent Statement: Not Applicable.

Data Availability Statement:
The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.